Please select the eligibility criteria that correspond to the clinical trial below.
Title: Follow up After Self-poisoning by General Practitioner- a Randomised Clinical Trial
Brief Summary: The study hypothesis is that follow up from general practitioner after hospitalization for self poisoning will decrease suicidal behaviour.


Options:
A: Inclusion Criteria:

* 18 - 64 yrs old
* patients who seek treatment at Grady Health System (GHS) after a suicide attempt
* African American
* speak English

Exclusion Criteria:

* cognitive impairments
* medical instability
B: Inclusion Criteria:

* Self Poisoning (according to the WHO definition)
* Ability to fill out questionnaire

Exclusion Criteria:

* Hospitalization into psychiatric ward
* Unknown address or ID
* Not registered with General Practitioner
* If institutionalized or in jail.
C: Inclusion criteria

Participants will be eligible to proceed in the study if they meet all of the following criteria (as determined in the screening session):

1. Men and women aged between 18-65 years of age
2. A diagnosis of BPD according to the Diagnostic Interview for Borderline patients or the Zanarini Rating Scale for Borderline Personality Disorder
3. Proficient in reading and writing English

Exclusion criteria

Potential participants who meet the criteria for any of the following will be excluded from participating in the study:

1. Clinical evidence of CNS pathology, neurological disorder, head injury, epileptic seizures or convulsions.
2. Currently pregnant or breastfeeding
3. A current DSM-IV-TR diagnosis of substance abuse or dependence disorder, or another Axis I disorder including a past or current diagnosis of schizophrenia, delusional (paranoid) disorder, schizoaffective disorder, bipolar I (mixed, manic, depressed or euthymic) or psychotic depression. Individuals with bipolar II will be included
4. Clinically significant and active evidence of liver or kidney disease, hematological, respiratory, endocrine or cardiovascular disease.
5. Use of prescription drugs that may cause relevant drug interactions with the study drug according to the summary of product characteristics: NMDAR antagonists (amantadine, ketamine, dextromethorphan), L-Dopa, dopamine agonists and cholinergic agonists.
6. Commencing new psychotherapy/ new medication during the trial period.
7. History of mental retardation or documented IQ below 75
D: Inclusion Criteria:

* Meets Diagnostic and Statistical Manual (DSM-IV) criteria for borderline personality disorder (BPD)
* Attempted suicide in the past 2 months
* At least one additional suicide attempt, suicide-related behavior, or self-injury episode in the past year
* Current suicidal ideation
* Able to be managed as an outpatient
* Not currently receiving optimum psychiatric treatment and agrees to notify study staff if any psychiatric care outside this study is sought. If care other than that permitted by the protocol is utilized, participants can no longer be enrolled in the study.
* Has a stable living arrangement at study entry
* Speaks English
* Willing and judged to be clinically able to undergo wash-out of psychotropic medications, except for occasional benzodiazepines use, for 2 to 6 weeks before treatment
* Females must be willing to use an effective method of birth control.

Exclusion Criteria:

* Meets the DSM-IV criteria for mental retardation or the following disorders: bipolar I, schizophrenia, delusional disorder, schizophreniform disorder, schizoaffective disorder, or psychotic disorder not otherwise specified (NOS)
* Needs priority treatment for acute medical illness or other debilitating problem, such as severe substance dependence or anorexia
* Pregnant
* Clinically too unstable to be maintained as an outpatient
* Has clearly failed adequate trials of fluoxetine and citalopram for a major depression in the past 2 years
* History of severe allergies, adverse drug reactions, or known allergy to fluoxetine or citalopram
* Clinically inadvisable for the participant to end current treatment
* Heart pacemaker body implant; other metal implants, such as shrapnel or surgical prostheses; or paramagnetic objects contained within the body, as assessed via a metal screening questionnaire, which may present a risk to the participant or interfere with the fMRI scan
* Diagnosed with Raynaud's disorder
* History of hypertension, cardiovascular disease, or abnormal electrocardiograms (EKGs)
* Claustrophobia or significant discomfort in enclosed space

Answer: B